RYZOLT Drug Patent Profile

When do Ryzolt patents expire, and what generic alternatives are available?

Ryzolt is a drug marketed by Purdue Pharma and is included in one NDA.

The generic ingredient in RYZOLT is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ryzolt

A generic version of RYZOLT was approved as tramadol hydrochloride by SUN PHARM INDS INC on June 19^th, 2002.

Summary for RYZOLT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	1
Patent Applications:	2,915
What excipients (inactive ingredients) are in RYZOLT?	RYZOLT excipients list
DailyMed Link:	RYZOLT at DailyMed

Recent Clinical Trials for RYZOLT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	Phase 2

See all RYZOLT clinical trials

Paragraph IV (Patent) Challenges for RYZOLT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYZOLT	Extended-release Tablets	tramadol hydrochloride	100 mg, 200 mg and 300 mg	021745	1	2009-06-18

US Patents and Regulatory Information for RYZOLT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-001	Dec 30, 2008		DISCN	Yes	No
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-002	Dec 30, 2008		DISCN	Yes	No
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-003	Dec 30, 2008		DISCN	Yes	No

Expired US Patents for RYZOLT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-002	Dec 30, 2008
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-001	Dec 30, 2008
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-001	Dec 30, 2008
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-003	Dec 30, 2008
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-003	Dec 30, 2008
Purdue Pharma	RYZOLT	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021745-002	Dec 30, 2008

International Patents for RYZOLT

See the table below for patents covering RYZOLT around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	241660	CONTROLLED-RELEASE FORMULATIONS OVERCOATED WITH PLASTICISED ETHYLCELLULOSE AND CURED AT ELEVATED TEMPERATURE AND HUMIDITY
Australia	7901594
Slovenia	1477162
Poland	304060
Finland	121620
Spain	2310686

Supplementary Protection Certificates for RYZOLT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0566709	SPC/GB04/012	United Kingdom		PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
2488169	C202330042	Spain		PRODUCT NAME: COCRISTAL DE TRAMADOL, OPCIONALMENTE EN FORMA DE UNA SAL FISIOLOGICAMENTE ACEPTABLE, Y CELECOXIB; NATIONAL AUTHORISATION NUMBER: 89051; DATE OF AUTHORISATION: 20230925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 89051; DATE OF FIRST AUTHORISATION IN EEA: 20230925
0566709	C300152	Netherlands		PRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405

RYZOLT Market Analysis and Financial Projection

Last updated: April 26, 2026

RYZOLT: Market dynamics and financial trajectory

RYZOLT is the brand name for dupilumab (marketed in different geographies under multiple brand names and pack formats). The drug’s market dynamics track the broader dupilumab franchise: high-potential growth driven by expanding labeled use, offset by pricing pressure, payer controls, and competitive entry in IL-4/IL-13 and adjacent biologic pathways. Financial trajectory is anchored by (1) persistent high demand for chronic inflammatory disease management, (2) durable uptake once patients are stabilized, and (3) ongoing label and formulation expansion that extends the addressable patient pool.

What is the market position of RYZOLT (dupilumab) by category?

RYZOLT’s market position is determined by how payers classify biologics across its labeled indications. Dupilumab is positioned as a premium, chronic-therapy biologic with payer intent to manage cost via step therapy, prior authorization, and center-of-excellence style management in some markets.

Primary commercial demand drivers

• Chronic disease treatment (high switching friction once on therapy)
• Biomarker-light prescribing relative to some specialty competitors
• Combination and line-of-therapy expansion when supported by clinical evidence
• Ongoing formulary inclusion efforts via manufacturer contracting and health economic dossiers

Key market headwinds

• Exclusivity and competition timelines across each major indication
• Biosimilar and “same pathway” product substitution as competitive density rises
• Pricing pressure through tendering and reference pricing mechanisms
• Payer tightening around initiation criteria and persistence thresholds

How do payer mechanics shape uptake and revenue timing?

Dupilumab’s revenue trajectory reflects payer gating more than pure incidence growth. The key mechanisms that influence commercialization speed and sustained revenue are:

1) Prior authorization and step therapy

Payers commonly require:

• Proof of prior topical/systemic treatment failure for dermatologic indications
• Documentation of disease severity and adherence
• Use-limiting criteria tied to labeling

This delays initial adoption and shifts revenue into later quarters once contracting matures.

2) Contracting structures and rebates

Global brands in this class typically rely on:

• Rebates linked to uptake and persistence
• Outcomes-based or “value” components in some territories
• Hospital and channel-specific pricing frameworks

These structures stabilize net price, but can compress list price growth.

3) Persistence economics

Dupilumab’s chronic profile supports higher persistence than short-course biologics. Revenue growth therefore tends to show:

• Slower initial ramp post-launch in each indication
• Then steadier retention after patients become stable on therapy
• Greater sensitivity to adverse event management and adherence support programs

What does the competitive landscape imply for financial trajectory?

Competition in IL-4/IL-13 and overlapping immunology segments matters because payer decisions often treat biologics as substitutable within a “class” even when mechanisms differ.

Competitive pressures to expect

• Same-pathway entrants that price aggressively or win formulary access via contracting
• Near-mechanism substitutes (other cytokine pathways with similar patient targeting)
• Switching friction that limits immediate share loss but slows recovery once lost

What this means for revenue

• Early-stage growth can be strong where clinical and formulary barriers are still being cleared.
• Later-stage growth becomes more about net price and share maintenance than pure volume expansion.
• Franchise revenue can keep compounding if the company sustains label expansion and maintains formulary coverage.

Financial trajectory: how to read RYZOLT’s revenue path

RYZOLT’s financial trajectory follows a recognizable pattern common to premium biologics:

Phase profile

1. Launch-to-adoption phase
   • Revenue grows slower than prescriptions because of payer approvals
   • Net revenue depends on contracting maturity and channel inventory discipline
2. Label expansion phase
   • Addressable market widens, increasing the pace of new patient starts
   • Retention supports steady revenue after patient stabilization
3. Maturity and competition phase
   • Growth shifts from “new starts” to “share and net price”
   • Growth rates typically decline as competitive density rises

Metrics that typically move first

• Prescriptions and new starts (volume)
• Then net sales per treated patient (price and mix)
• Then long-term persistence (retention and churn)

Where does RYZOLT’s market growth come from next?

For dupilumab, commercial expansion is driven by:

• Additional labeled indications supported by trial outcomes
• Expanded patient subgroups within existing indications
• Improved administration convenience through formulation and device improvements (where applicable)
• Region-by-region formulary wins that convert eligible demand into reimbursed demand

In practice, these factors add incremental starts and reduce the gap between clinical eligibility and reimbursed eligibility.

How do macro and healthcare policy changes affect net revenue?

United States

• Higher use of prior authorization and utilization management
• Pharmacy benefit versus medical benefit channel shifts affecting reimbursements and claims timing
• Price negotiations and Medicare Part B dynamics influencing settlement terms indirectly

Europe

• Tendering, reference pricing, and national reimbursement tightening can slow net price growth
• Biosimilar pressure in adjacent biologic areas can spread competitive discounting

Business implications for R&D and investment

For R&D planners

• Target commercial success hinges on payer-readiness in the first 12 to 24 months post-evidence
• Trial-to-reimbursement alignment (endpoint selection and subgroup definitions) matters for uptake speed
• Competitive strategy should assume net price compression once similar products secure formulary placement

For investors

• Model revenue with a bifurcated structure:
  • Volume driven by label breadth and formulary conversion
  • Net price influenced by contracting, rebate, and competitive penetration
• Revenue durability depends on retention and low discontinuation driven by disease control consistency

Key market-dynamics table for RYZOLT (dupilumab)

Dimension	Primary driver	Typical impact on revenue shape	Main risk
Patient starts	Label breadth + payer approval	Growth accelerates after contracting	Step therapy and documentation barriers
Net price	Rebates, contracting, channel mix	Net price stabilizes after early period	Competitive discounting and tendering
Persistence	Chronic disease control	Revenue remains steadier over time	Tolerability, switching, adherence issues
Competition	IL-4/IL-13 peers and substitutes	Growth slows in maturity	Share loss and net price compression
Policy	Utilization management + negotiations	Can shift timing of claims and settlements	Tightening criteria reduces eligible starts

Key Takeaways

• RYZOLT’s market dynamics are dominated by payers, not just clinical demand, with prior authorization and step therapy shaping quarterly revenue timing.
• The financial trajectory for dupilumab-style franchises typically shows launch ramp, label-driven acceleration, then maturity-driven growth deceleration as competition increases.
• Long-run performance depends on persistence and net price management via contracting, not only on new patient starts.
• Competitive pressure is most damaging once formulary wins translate into sustained switching and broader eligible populations shift to alternatives.

FAQs

1) What controls how quickly RYZOLT revenue grows?
Payer authorization speed and formulary conversion for each indication, which determine whether clinical eligibility turns into reimbursed starts.

2) What metric best forecasts RYZOLT net revenue direction?
New starts and treated-patient mix in the short term, followed by net sales per treated patient after contracting and rebate settlement effects flow through.

3) How does competition usually affect RYZOLT’s revenue?
It slows growth by compressing net price and shifting share, with persistence limiting immediate revenue collapse but reducing upside versus earlier periods.

4) Does RYZOLT’s chronic use improve revenue stability?
Yes, chronic biologic treatment typically supports steadier revenue through higher persistence once patients stabilize.

5) What is the most reliable lever for extending RYZOLT’s market growth?
Ongoing labeled expansion and subgroup inclusion that expands reimbursed addressable demand while maintaining formulary access and contracting strength.

---

References

[1] APA: FDA. “Drug Approval Information.” US Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases (accessed 2026-04-26).
[2] APA: EMA. “European public assessment reports (EPAR) and product information.” European Medicines Agency. https://www.ema.europa.eu/en (accessed 2026-04-26).
[3] APA: IQVIA Institute. “Medicines Use and Spending.” IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports (accessed 2026-04-26).
[4] APA: Centers for Medicare & Medicaid Services. “Part B Drug Payment and Reimbursement.” CMS. https://www.cms.gov (accessed 2026-04-26).